US real-world study of the burden of medication in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

#4223

Introduction: Patients with NETs experience a range of comorbidities, and often present with carcinoid syndrome (CS).

Aim(s): To understand the burden of concomitant medications on patients with GEP-NETs.

Materials and methods: Adults with GEP-NETs (identified by ICD-10-CM code), with or without CS, who initiated first-line NETs treatment (index date) and had ≥1 inpatient or ≥2 distinct outpatient claims (study period, Jan 1, 2016–Dec 31, 2022) were identified from the US MarketScan database and matched (age, sex, insurance type) with up to four adults without cancer (reference group). Frequency of non-cancer comorbidities (≥1 diagnosis claim) was calculated. At 3 months (0–90 days) post-index, mean total medication counts and frequency distributions (Chi-squared test) were compared.

Conference:

Presenting Author:

Authors: Chan J, Houchard A, Pommie C, Ribeiro-Oliveira Jr A, Starr J,

Keywords: gastroenteropancreatic, neuroendocrine tumor, concomitant medication, burden,